Data on the incidence and possible effects of acute respiratory infections (ARIs) caused by respiratory syncytial virus (RSV) in pregnant women are scarce. This infection is an under-recognised disease, primarily due to a lack of diagnostic techniques to establish the possible viral aetiology of ARIs, especially during RSV epidemic periods. Chu et al.1 reported RSV detection in 0.4% of pregnant women and in 2% of those with respiratory symptoms.
A retrospective study covering the last four RSV epidemic seasons (2021–2025) was conducted to determine the incidence of RSV ARIs in the pregnant population. A pharyngeal swab was taken from each pregnant woman with a suspected ARI attending emergency care and tested for respiratory viruses using a commercial real-time polymerase chain reaction (PCR) assay (Allplex Respiratory Assay; Seegene, Korea).
Over the course of the study, 95 pregnant women were studied: 20 (21%) in the 2021–2022 season, 25 (26.3%) in the 2022–2023 season, 22 (23.1%) in the 2023–2024 season and 28 (29.4%) in the 2024–2025 season. Overall, 33 positive cases (34.7%) were detected: 15 rhinovirus (45.4%), seven influenza A (H1N1) (21.2%), five adenovirus (15.1%), four RSV (12.1%) and two metapneumovirus (6.1%). RSV accounted for 4.2% of all ARIs detected in this cohort of pregnant women. Cases were detected in the last three seasons, representing 4%, 4.5% and 3.5% of the pregnant women studied in each season, respectively. All four RSV cases were identified as RSV-B. Only one pregnant woman infected with RSV developed pneumonia and required hospital admission (25%), while the rest had fever and mild respiratory symptoms.
The few studies on the burden of RSV infection in pregnant women are somewhat contradictory. In Nepal,1 it was found to be 3.9 cases per 1000 person-years overall compared to 0.03 cases in Mongolia.2 However, aetiological diagnosis was only performed in 0.4% (14/3693) and 0.3% (4/1260) of cases in those countries, respectively, meaning its true incidence has yet to be established.
Meanwhile, Regan et al.3 reported that in the period 2010–2016, out of 846 pregnant women hospitalised for ARI, 21 (2%) were RSV-positive and eight (38%) of these developed pneumonia; RSV-infected women were more likely to develop pneumonia than uninfected women. Hause et al.4 reported that out of 25 pregnant women infected with RSV, 40% required hospital admission also for pneumonia, 90% of whom had some comorbidity, primarily obesity (50%) and asthma (20%). However, Chaw et al.2 reported that 68% of women infected with RSV required hospitalisation compared to 11.8% of women infected with influenza.
In our study, RSV accounted for 4.2% of ARIs diagnosed in pregnant women, a lower percentage than the 10% reported by Hause et al.,4 although in our case, the number of pregnant women is low and the findings should be interpreted with caution. It has been observed that pregnant women with comorbidities are 1.4 times more likely to develop RSV pneumonia.5 In our study, only one pregnant woman (25% of the total) developed pneumonia and required hospital admission, although she did not have any underlying condition.
The study by Madhi et al.6 found that RSV infections were two to four times more frequent in the second half of pregnancy and the overall incidence was 1.6% in HIV-positive women compared to 1.3% in HIV-negative women. One of the characteristics described in this study is that most of the pregnant women did not have fever, although their respiratory symptoms were severe enough to require emergency medical care. While 4.7% of RSV infections in this study developed pneumonia, the remainder had no complications affecting the course of pregnancy or the newborn. The meta-analysis conducted by Kenmoe et al.7 on 8126 pregnant women spanning the period 2010–2022 concluded that the percentage of ARIs in these women ranges from 0.9% to 10.7%, with an overall incidence of 26 per 1000 person-years.
In view of our results and the findings of other studies,2,3,7,8 it can be concluded that RSV ARIs during pregnancy are rare with low morbidity, although larger studies are needed to draw a definitive conclusion.
CRediT authorship contribution statementBoth authors (JR and AL) have contributed equally to the development, planning and implementation of the study.
Ethical considerationsThere are no ethical considerations of any kind as this study did not involve animal testing, nor did it involve interventions on human patients or subjects, and it is not a clinical trial.
Declaration of Generative AI and AI-assisted technologies in the writing processNo artificial intelligence has been used for this work.
FundingNo funding of any kind was received for conducting this study.
The authors declare that they have no conflicts of interest.

